| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery |
2019-10-07 |
| Technical Univ Denmark–Inscripta: genome engineering technology, 201910 supply existent TUD NNFCB early customer Onyx Genome Engineering platform |
2019-10-01 |
| STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings |
2019-09-30 |
| Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures |
2019-09-18 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Alder Biopharmaceuticals–Lundbeck: investment, 201909–201910 acquisition tender offer in cash + CVRs up to $1.95b net of cash |
2019-09-16 |
| Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule RnD to Orion Pharma |
2019-09-11 |
| Genmab–Tempus Labs: AI-based drug discovery, 201909– strateg collab multi-year RnD targets + biomarker for personalised cancer drugs |
2019-09-09 |
| Sigrid Therapeutics–Axilium Capital: investment, 201909 financing round totalling $1.6m incl co-investor Axilium Capital |
2019-09-05 |
| Sigrid Therapeutics–Joyance Partners: investment, 201909 financing round totalling $1.6m incl co-lead investor Joyance Partners |
2019-09-05 |
| Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-investor Karsten Inde |
2019-09-05 |
| Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-lead investor Pär Gellerfors |
2019-09-05 |
| Sigrid Therapeutics–SEVERAL: investment, 201909 financing round $1.6m led by Joyance Partners + Pär Gellerfors |
2019-09-05 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| Protelux (RU)–Unibio: protein production from methane, 201908 collab existing buidling + operating plant for Uniprotein production in Russia |
2019-08-28 |
| Unibio–SEVERAL: investment, 201908 financing round $15m (£12.4m) from existing + new shareholders led by West Hill Capital |
2019-08-28 |
| Unibio–West Hill Capital: investment, 201908 financing round totalling $15m (£12.4m) incl lead investor West Hill Capital |
2019-08-28 |
| Nanovi–SEVERAL: investment, 201908 financing round DKK19m from existing investors |
2019-08-27 |
| Biotheus–Alligator Bioscience: therapeutic antibodies, 201908– license to Ab from Alligator-Gold library for bispecific molecules for Greater China |
2019-08-20 |
| Ellab–EQT: investment, 201908–201909 acquisition €na majority share by EQT Mid Market Europe Fund from IK VIII Fund |
2019-08-07 |
| Glycomine–Chiesi: investment, 201908 financing round Series B totalling $33m incl existing + co-investor Chiesi Ventures |
2019-08-07 |
| Glycomine–Novo Group: investment, 201908 financing round Series B totalling $33m incl lead investor Novo Holdings A/S |
2019-08-07 |
| Glycomine–SEVERAL: investment, 201908 financing round Series B $33m led by Novo Holdings A/S |
2019-08-07 |
| Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB |
2019-08-05 |
| Babylon Health–SEVERAL: investment, 201908 financing round $550m from existing + new investors |
2019-08-02 |
| Alizé Pharma–Eurazeo: investment, 201907 financing round Series A €67m incl Kurma Partners |
2019-07-31 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| OncoImmunity–NEC: investment, 201907 acquisition by NEC and renamed NEC OncoImmunity AS |
2019-07-29 |
| Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market |
2019-07-22 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties |
2019-07-12 |
| Nanoform–Notch Communications: public relations, 201907 service existent by Notch |
2019-07-10 |
| IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S |
2019-07-08 |
| IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al |
2019-07-08 |
| Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 |
2019-07-05 |
| Nanoform–SEVERAL: investment, 201907 private placement €10m incl Ilmarinen Mutual Pension Insurance + Mandatum Life Insurance |
2019-07-03 |
| ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics |
2019-07-01 |
| Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties |
2019-07-01 |
| Oncopeptides–SEVERAL: investment, 201906 directed share issue SEK727m ($78m) of 5.015m new shares at SEK145/share |
2019-06-27 |
| Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures |
2019-06-26 |
| UmanDiagnostics–Quanterix: investment, 201906–201907 acquisition $16m in cash + $6.5m in common stock |
2019-06-26 |
| Forendo Pharma–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Sword Health–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Karolinska Institutet–BGI: DNA sequencing, 201906– collab using DNBSEQ techn for shotgun metagenomics data from microbiome biobank MGI Tech |
2019-06-20 |
| Cellink–SEVERAL: investment, 201906 capital raising SEK148.5m with institutional investors |
2019-06-18 |
| Spero Therapeutics–Novo Group: investment, 201906– direct offering common stock up to $10m in two tranches of $5m to Novo REPAIR Fund |
2019-06-13 |
| JnJ–Genmab: antibody cancer drug, 201906– collab + excl ww license + option agreem for HexaBody-CD38 monoclonal antibody |
2019-06-11 |
| Merck (US)–Agilent: molecular companion diagnostics, 201906 collab existent developm of PD-L1 IHC 22CR pharmDx for use with Keytruda |
2019-06-11 |
| Saga Diagnostics–Fårö Capital: investment, 201906 financing round totalling SEK40m (€3.7m) incl existing + co-investor Fårö Capital |
2019-06-11 |
| Saga Diagnostics–Gunnar Nilsson Cancer Foundation: investment, financing round totalling SEK40m (€3.7m) incl existing + co-investor GNCF |
2019-06-11 |
| Saga Diagnostics–Hadean Ventures: investment, 201906 financing round totalling SEK40m (€3.7m) incl new + lead investor Hadean Ventures |
2019-06-11 |
| Saga Diagnostics–SEVERAL: investment, 201906 financing round SEK40m (€3.7m) led by new investor Hadean Ventures |
2019-06-11 |
| Everest Medicines–Calliditas Therapeutics: Nefecon, 201906– license $15m upfront + $106m milestones + royalties developm + sale for IgAN in China + SG |
2019-06-10 |
| Yingsheng Biotechnology–Biotage: clinical mass spectrometry, 201906– collab strategic + OEM sale in China by Shandong Yingsheng Biotechnology |
2019-06-04 |
| Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share |
2019-05-28 |
| Fujifilm–Genovis: enzymes, 201905– collab distribution of SmartEnzymes in Japan + Taiwan + Singapore by Fujifilm Wako Pure Chemical |
2019-05-16 |
| Symphogen–Essex Woodlands: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder Essex Woodlands HC |
2019-05-15 |
| Symphogen–Novo Group: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder Novo Holdings |
2019-05-15 |
| Symphogen–PKA: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder PKA |
2019-05-15 |
| Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders |
2019-05-15 |
| Symphogen–Sunstone Life Science: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder Sunstone |
2019-05-15 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck |
2019-05-06 |
| Labster–Balderton Capital: investment, 201904 financing round Series B totalling $21m incl existing + co-investor Balderton Capital |
2019-04-25 |
| Labster–EduCapital: investment, 201904 financing round Series B totalling $21m incl existing + co-investor EduCapital |
2019-04-25 |
| Labster–Entangled Group: investment, 201904 financing round Series B totalling $21m incl existing + co-investor Entangled Group |
2019-04-25 |
| Labster–Nordic Makers: investment, 201904 financing round Series B totalling $21m incl existing + co-investor Nordic Makers |
2019-04-25 |
| Labster–Northzone: investment, 201904 financing round Series B totalling $21m incl existing + co-investor Northzone |
2019-04-25 |
| Labster–Owl Ventures: investment, 201904 financing round Series B totalling $21m incl new + lead investor Owl Ventures |
2019-04-25 |
| Labster–PERSON: investment, 201904 financing round Series B totalling $21m incl existing + co-investor David Helgason |
2019-04-25 |
| Labster–SEVERAL: investment, 201904 financing round Series B $21m led by Owl Ventures |
2019-04-25 |
| Labster–Swisscom: investment, 201904 financing round Series B totalling $21m incl co-investor Swisscom Ventures |
2019-04-25 |
| United States (govt)–Cobo Technologies: genome editing, 201904– collab Cobo beomes member of NIST Genome Editing Consortium |
2019-04-15 |
| Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk |
2019-04-12 |
| Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. |
2019-04-09 |
| Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors |
2019-04-04 |
| Gesynta Pharma–Sweden (govt): investment, 201904 financing round totalling €6m incl lead investor Industrifonden |
2019-04-04 |
| Chr. Hansen–Lonza: microbiomic treatment, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments |
2019-04-02 |
| Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors |
2019-03-26 |
| Cytena–SEVERAL: investment, 201903 financing round Series A €3m from HTGF + two private investors |
2019-03-26 |
| Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine |
2019-03-26 |
| Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc |
2019-03-21 |
| Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri |
2019-03-12 |
| Biogen–Fujifilm: investment, 201903–201908 acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark |
2019-03-12 |
| Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP |
2019-03-11 |
| Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge |
2019-03-11 |
| Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office |
2019-03-11 |
| Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners |
2019-03-11 |
| Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners |
2019-03-11 |
| Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs |
2019-03-04 |
| CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility |
2019-03-01 |
| Mobidiag–Consilium: public relations, 201902 service existent by CSC |
2019-02-25 |
| Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group |
2019-01-22 |
| Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital |
2019-01-22 |
| Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals |
2019-01-22 |
| Samplix–EU (govt): grant, 201901– Horizon 2020 SME Instrument Program Grant €1.9m |
2019-01-10 |
| BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors |
2019-01-09 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
